The North America Antimicrobial Susceptibility Testing Market would witness market growth of 5.4% CAGR during the forecast period (2022-2028).
The overuse and misuse of antibiotics leading to antimicrobial resistance (AMR) and the rising utilization of antimicrobial susceptibility testing by biotechnological, biopharmaceutical, and pharmaceutical companies are major factors for the rapid expansion of the antimicrobial susceptibility testing market.
In addition, the increasing incidence of hospital-acquired infections (HAIs), the expansion of the patient population (especially in emerging nations), and the government's greater awareness of the need to battle antimicrobial resistance are anticipated to propel the market even further. Moreover, testing evaluates therapeutic services given by clinics, hospitals, and national infectious disease control and preventive programs. As a result of mutations in microbial genes, scientists are now compelled to undertake continuous surveillance of resistance patterns.
According to the Antibiotic Resistant Risks in the United States report, funding from the CDC's AR Solutions Initiative will support all 50 state health departments, many local health departments, Guam, Puerto Rico, and the U.S. Virgin Islands in 2020. From 2016 to 2022, the CDC invested in over 500 novel antimicrobial resistance programs in over 50 countries to prevent the spread of resistance both locally and globally. The well-established awareness campaigns for precision medicine and the use of antimicrobial testing, advantageous government initiatives, and a rising number of collaborative researches are some of the anticipated market growth drivers.
The US market dominated the North America Antimicrobial Susceptibility Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,293 million by 2028. The Canada market is poised to grow at a CAGR of 7.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 6.9% during (2022 - 2028).
Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development and Epidemiology & Others. Based on Method, the market is segmented into Automated Susceptibility Testing Instruments, Disk Diffusion, Etest Method, Agar Diffusion, and Genotyping Method. Based on Type, the market is segmented into Antibacterial, Antifungal, Antiparasitic, and Others. Based on End User, the market is segmented into Hospitals & Diagnostic centers, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Clinical Research Organizations. Based on Product, the market is segmented into Automated Laboratory Instruments, Manual Laboratory Instruments, Culture & Growth Media and Consumables. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Antimicrobial Susceptibility Testing Market is Predict to reach $4.9 Billion by 2028, at a CAGR of 5.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, Bruker Corporation, Accelerate Diagnostics, Inc., HiMedia Laboratories Pvt. Ltd., and F. Hoffmann-La Roche Ltd.
By Application
By Method
By Type
By End User
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 